ArticleBriefings in bioinformatics2026
ToxMamba: a novel method for toxic peptide prediction based on the fusion of pretrained embeddings and multi-scale state space models.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Peptide therapeutics offer great promise in drug discovery, yet the accurate identification of peptide toxicity remains essential for both safety assessment and biodefense. We developed ToxMamba, a toxic peptide prediction framework that integrates Implicit Structure Model (ISM)-derived pretrained embeddings, state space models, multi-scale feature learning, and ensemble inference. Built upon the Mamba architecture, ToxMamba enables efficient sequence modeling and captures contextual patterns across multiple receptive fields from parallel branches. On the independent test set, ToxMamba consistently surpasses existing methods, improving the F1 score and Matthews Correlation Coefficient by 3.9-18.3 and 7.5-46.9 percentage points, respectively. Ablation analyses further showed that Mamba-based models generally achieved stronger overall performance than Transformer-, Convolutional Neural Network-Long Short-Term Memory-Attention-, and Kolmogorov-Arnold Network-based variants. Feature visualization showed that ISM embeddings yielded clearer separation between toxic and non-toxic peptides in the latent space. Intermediate-layer feature analysis highlighted residue-level regions associated with toxicity-related sequence motifs, supporting the biological interpretability of ToxMamba. Overall, this study provides an efficient and interpretable computational framework for high-throughput toxic peptide screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.